ABPO Stock Chart & Stats
$0.14
-$0.18(-12.24%)
At close: 4:00 PM EST
$0.14
-$0.18(-12.24%)
Day’s Range― - ―
52-Week Range$0.09 - $13.67
Previous Close$1.32
VolumeN/A
Average Volume (3M)4.50M
Market Cap
$1.25M
Enterprise Value-$4.58M
Total Cash (Recent Filing)$5.40M
Total Debt (Recent Filing)$294.00K
Price to Earnings (P/E)0.2
Beta1.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding5,896,048
10 Day Avg. Volume2,638,066
30 Day Avg. Volume4,496,030
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.57K
Enterprise Value/Market Cap-3.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.70
Enterprise Value/Ebitda-1.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)-6.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing AvailabilityAccess to a $50 million equity line could ease capital constraints and reduce the need for more dilutive financing, supporting continued development activities.
Strategic CollaborationA collaboration with an established partner that covers clinical costs while sharing profits evenly improves cash efficiency and enhances commercialization potential for key assets.
Bears Say
Analyst SentimentAn analyst downgrade citing strategic uncertainty and a financing overhang may weaken market confidence and put downward pressure on the stock.
Liquidity RiskLow cash reserves combined with a sustained multi-million dollar cash burn elevate the likelihood of near-term capital raises that could dilute existing shareholders.
Pipeline StrategyUnclear strategic direction for the bispecific antibody portfolio increases execution risk and makes it harder for investors to evaluate future growth prospects.
Abpro Holdings News
ABPO FAQ
What was Abpro Holdings’s price range in the past 12 months?
Abpro Holdings lowest stock price was $0.09 and its highest was $13.67 in the past 12 months.
What is Abpro Holdings’s market cap?
Abpro Holdings’s market cap is $1.25M.
When is Abpro Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Abpro Holdings’s earnings last quarter?
Currently, no data Available
Is Abpro Holdings overvalued?
According to Wall Street analysts Abpro Holdings’s price is currently Overvalued.
Does Abpro Holdings pay dividends?
Abpro Holdings does not currently pay dividends.
What is Abpro Holdings’s EPS estimate?
Abpro Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Abpro Holdings have?
Abpro Holdings has 5,896,048 shares outstanding.
What happened to Abpro Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Abpro Holdings?
Currently, no hedge funds are holding shares in ABPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abpro Holdings
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Technical Analysis
Can-Fite BioPharma
―
XTL Biopharmaceuticals Sponsored ADR
―
Cellectar Biosciences
―
Cocrystal Pharma
―
―
Ownership Overview
12.19% Insiders
0.17% Mutual Funds
<0.01% Other Institutional Investors
87.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---